Vaccines Demonstrate Long-Term Effectiveness Against HPV-Related Cervical Cancer

Recent research underscores the proven effectiveness of HPV vaccines in providing lasting protection against cervical cancer. A comprehensive study conducted in Denmark analyzed cervical samples from women vaccinated as girls, revealing a significant decline in high-risk HPV types 16 and 18—responsible for the majority of cervical cancers. Over a seven-year period, the prevalence of these types in vaccinated women dropped to less than 1% from an initial 15-17%, indicating near-elimination of these high-risk strains through vaccination. Meanwhile, unvaccinated women still exhibited a 5% prevalence, strongly suggesting the development of herd immunity within the population.

The study involved testing up to three consecutive cervical cell samples from 17,252 women aged 22-30, enrolled between 2017 and 2024. Findings showed that although vaccines have dramatically reduced the presence of HPV types 16/18, infections with other high-risk HPV types not covered by current vaccines remain prevalent in both vaccinated and unvaccinated women. Interestingly, vaccinated women showed a higher incidence of infection with these non-vaccine high-risk types, prompting discussions on potential adjustments to cervical screening strategies.

Given the low occurrence of vaccine-covered HPV types in vaccinated populations, researchers suggest that less intensive screening might be appropriate until women vaccinated with the 9-valent vaccine reach screening age. Overall, these findings reinforce the importance of HPV vaccination programs and highlight the need to consider tailored screening protocols as vaccination coverage expands.

This research illuminates the substantial impact of vaccination on reducing cervical cancer risk, emphasizing the importance of ongoing immunization efforts and updated screening approaches for optimal public health outcomes.

Source: https://medicalxpress.com/news/2025-07-vaccines-real-world-evidence-stable.html